Biosynth Life Sciences India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.50 M
as on 24-10-2024
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -110.34%
(FY 2023)
- Ebitda -171.52%
(FY 2023)
- Net Worth -2.69%
(FY 2023)
- Total Assets -5.88%
(FY 2023)
About Biosynth Life Sciences India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Srinivasan Ranganathan, Venkateswaran Natarajan, and Ganesan Anandanarayanan serve as directors at the Company.
- CIN/LLPIN
U24234TN2006PLC059506
- Company No.
059506
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2006
- Date of AGM
26 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Biosynth Life Sciences India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srinivasan Ranganathan  | Director | 23-Jan-2012 | Current |
| Venkateswaran Natarajan | Director | 06-Feb-2014 | Current |
| Ganesan Anandanarayanan | Director | 14-Mar-2024 | Current |
Financial Performance and Corporate Structure Insights of Biosynth Life Sciences India.
Biosynth Life Sciences India Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 110.34% decrease in profit. The company's net worth dipped by a decrease of 2.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biosynth Life Sciences India?
In 2023, Biosynth Life Sciences India had a promoter holding of 15.00% and a public holding of 85.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Visaka Cement Industry Ltd,Inactive For E-Filing 30 years 4 monthsSrinivasan Ranganathan is a mutual person
- India Cements Infrastructures LimitedActive 11 years 10 months
Srinivasan Ranganathan is a mutual person
Industrial Chemicals And Monomers LimitedActive 45 years 4 monthsSrinivasan Ranganathan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biosynth Life Sciences India?
Unlock and access historical data on people associated with Biosynth Life Sciences India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biosynth Life Sciences India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biosynth Life Sciences India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
